Pain Management · Chronic Coccydynia
The ongoing clinical trial comparing RFA techniques for chronic coccydynia could significantly influence treatment protocols in pain management. The outcomes may lead to shifts in clinical practice and market dynamics, affecting how pain management therapies are adopted and utilized.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/10/2026, 6:30:37 PM
Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The ongoing clinical trial comparing RFA techniques for chronic coccydynia could significantly influence treatment protocols in pain management. The outcomes may lead to shifts in clinical practice and market dynamics, affecting how pain management therapies are adopted and utilized. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 2 ranked evidence items (1 high-relevance).
Success of either technique could shift clinical practice and affect market dynamics for pain management therapies. The strongest clinical anchor is Comparison of Single- and Double-Level Radiofrequency Ablation for Chronic Coccydynia (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In pain, 1 regulatory and 1 competitive items passed relevance filtering for pain management therapies.
The most relevant competitive pressure comes from Pfizer's Ibuzatrelvir Study Targets High-Risk COVID-19 Patients (Humanexa Signals) — sponsor/company relevance (pfizer). Results may influence treatment protocols in pain management, impacting the adoption of RFA techniques.
Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The trial is unlikely to have immediate regulatory implications, but results may inform future clinical guidelines rather than regulatory approvals.
FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View sourceComparison of Single- and Double-Level Radiofrequency Ablation for Chronic Coccydynia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrevalence and Risk Factors for Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery : The EVATHO Prospective Bicentric Cohort Study.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceBowen Therapy and McGill Stabilization Exercises in Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAcupuncture for Heel Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAssessing the Efficacy of High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePfizer's Ibuzatrelvir Study Targets High-Risk COVID-19 Patients
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
4D Flow MRI Study Aims to Improve Risk Stratification for Variceal Bleeding in Cirrhosis
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFactors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceImmunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceElevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePeer-delivered combined EMD and imagery rescripting for traumatized Chinese university students: RCT.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing clinical trial comparing RFA techniques for chronic coccydynia could significantly influence treatment protocols in pain management. The outcomes may lead to shifts in clinical practice and market dynamics, affecting how pain management therapies are adopted and utilized.
Depending on the trial results, there could be a notable impact on market share for companies involved in pain management therapies, particularly those offering RFA solutions.
The trial is unlikely to have immediate regulatory implications, but results may inform future clinical guidelines rather than regulatory approvals.
Monitor trial results and subsequent changes in treatment guidelines for chronic coccydynia.
Track for follow-up milestones; no immediate action required.